Correct Answer: A. Great saphenous vein
The great saphenous vein (GSV) is the gold standard for femoropopliteal bypass grafting because it offers superior long-term patency rates (>70% at 5 years) compared to all synthetic alternatives. This superiority stems from three critical factors: (1) biological compatibility — the vein is autologous, eliminating immunological rejection and chronic inflammation; (2) endothelial function — native endothelium produces vasodilators (nitric oxide, prostacyclin) and resists thrombosis better than synthetic surfaces; (3) remodeling capacity — the vein adapts to hemodynamic stress, reducing intimal hyperplasia, the primary cause of late graft failure. In Indian vascular surgery practice, GSV remains the preferred conduit for infrainguinal bypass (femoropopliteal and femorotibial) in all patients where adequate vein diameter (≥3.5 mm) and quality are present. The vein is harvested from the medial thigh, avoiding damage to saphenous nerve branches. Even in diabetic patients with diffuse atherosclerosis (common in India), GSV patency exceeds synthetic grafts. Current guidelines (including Indian vascular society recommendations) reserve synthetic grafts only when GSV is unavailable, inadequate, or previously used.
Why the other options are wrong
B. Short saphenous vein — The short saphenous vein (SSV) has smaller diameter (3–4 mm vs GSV 4–6 mm), thinner wall, and higher rates of early thrombosis and intimal hyperplasia. SSV is located in the posterior calf, making harvest technically difficult and prone to sural nerve injury. Long-term patency is significantly inferior to GSV. SSV is reserved only as a last-resort conduit when GSV is absent or severely diseased, and even then, outcomes are poor in Indian patient cohorts with advanced peripheral arterial disease. C. Dacron — Dacron (polyester) is a synthetic graft with 5-year patency rates of 40–50% in femoropopliteal position — substantially lower than GSV. Dacron triggers chronic inflammatory response, promotes intimal hyperplasia at anastomotic sites, and lacks endothelial function. It is thrombogenic and requires lifelong anticoagulation in many cases. Dacron is reserved for aortic grafts or when vein is unavailable; using it as first-line for infrainguinal bypass violates current vascular surgery standards and leads to graft failure within 2–3 years in Indian patients. D. Polytetrafluoroethylene — PTFE (Teflon) has the worst patency in femoropopliteal position (30–40% at 5 years), even inferior to Dacron. PTFE is highly thrombogenic, lacks biological integration, and develops severe intimal hyperplasia at the distal anastomosis. It is occasionally used for above-knee femoropopliteal bypass or when vein is absolutely unavailable, but never as first-line. The NBE trap here is that students may recall PTFE's use in dialysis access and mistakenly apply it to arterial bypass.
High-Yield Facts
- Great saphenous vein (GSV) has >70% 5-year patency in femoropopliteal bypass — gold standard for infrainguinal grafting.
- Synthetic grafts (Dacron, PTFE) have 30–50% 5-year patency in femoropopliteal position and are reserved for aortic or when vein unavailable.
- Short saphenous vein is smaller (3–4 mm), technically difficult to harvest, and has inferior patency; used only as last resort.
- Endothelial function of autologous vein produces nitric oxide and resists thrombosis, explaining GSV superiority over synthetic conduits.
- Intimal hyperplasia at anastomotic sites is the primary cause of late graft failure; native vein remodeling reduces this better than synthetics.
Mnemonics
VEIN > SYNTHETIC Vein (autologous) > Endothelial function > Intimal hyperplasia resistance > No rejection. Always choose vein for infrainguinal bypass if available. Synthetic reserved for aortic or when vein absent. GSV Patency Rule Great saphenous = Gold standard (>70% at 5 years). Short saphenous = Second-rate (poor outcomes). Synthetic = Suboptimal (<50% at 5 years).
NBE Trap
NBE may pair "synthetic graft" with "easier to harvest" or "no vein damage" to lure students into choosing Dacron/PTFE for convenience. The trap ignores that long-term patency and patient outcomes are paramount in vascular surgery — GSV harvest morbidity is minimal compared to graft failure requiring re-operation.
Clinical Pearl
In Indian practice, diabetic patients with critical limb ischemia often present late with diffuse atherosclerosis and limited vein options. Even in these challenging cases, GSV (if available) offers superior limb salvage rates compared to synthetic grafts — a lesson reinforced by high re-amputation rates when synthetics are used as first-line in our patient population.
_Reference: Bailey & Love Ch. 52 (Vascular Surgery); Harrison Ch. 242 (Peripheral Arterial Disease)_